Immunoprecise Antibodies Ltd
NASDAQ:HYFT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Wallstreet online AG
XETRA:WSO1
|
DE |
Immunoprecise Antibodies Ltd
Accounts Payable
Immunoprecise Antibodies Ltd
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immunoprecise Antibodies Ltd
NASDAQ:HYFT
|
Accounts Payable
CA$3.3m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
34%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Accounts Payable
$3.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
|
|
Danaher Corp
NYSE:DHR
|
Accounts Payable
$1.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
|
|
Waters Corp
NYSE:WAT
|
Accounts Payable
$103.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Accounts Payable
$602m
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Accounts Payable
$3.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
38%
|
|
Immunoprecise Antibodies Ltd
Glance View
ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The company is headquartered in Austin, Texas. The company is advancing Bio-Native AI at the intersection of biology and computation. Its LENSai and HYFT platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. The core of its operations encompasses a diverse suite of proprietary technologies that aid in the exploration, discovery, and development of novel drugs and biologics. Integrated within its wet lab infrastructure is a diverse array of in silico technologies. As an end-to-end service provider of antibody discovery and development, its computational methodologies allow the Company to perform detailed and comprehensive evaluations across various stages of biologic discovery and development. The company is involved in antibody characterization studies, which encompass affinity measurements, epitope landscape profiling, and others.
See Also
What is Immunoprecise Antibodies Ltd's Accounts Payable?
Accounts Payable
3.3m
CAD
Based on the financial report for Jan 31, 2026, Immunoprecise Antibodies Ltd's Accounts Payable amounts to 3.3m CAD.
What is Immunoprecise Antibodies Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
34%
Over the last year, the Accounts Payable growth was -24%. The average annual Accounts Payable growth rates for Immunoprecise Antibodies Ltd have been -8% over the past three years , 6% over the past five years , and 34% over the past ten years .
